GoldenGolden
Advanced Search
AI Medical Service

AI Medical Service

An artificial intelligence and healthcare company making software for the early detection of gastrointestinal cancers.

All edits by  Aime Anne Nisay 

Edits on 1 Apr, 2020
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 1 Apr, 2020
Edits made to:
Article (+5/-5 characters)
Article

AI Medical Service is an artificial intelligence and healthcare company making software for the early detection of gastrointestinal cancers that is headquartered in Toshima, TokyoTokyo and was founded in 2017 by Tomohiro Tada. The company's software analyzes endoscope images to support endoscopists and help doctors make diagnoses.

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 1 Apr, 2020
Edits made to:
Article (+3/-3 characters)
Article
We foresee an irreversible trend of doctors diagnosing cancer in collaboration with AI in the near future. Supported by the world’s leading medical institutions and specialists in the field and led by experienced management, the endoscopy AI developed by AIMAIM has huge potential to help endoscopists and patients globally.
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 1 Apr, 2020
Edits made to:
Article (+26/-26 characters)
Article

On October 4, 2019 AI Medical Service announced raising ¥4.6 billion ($42.9 million USD) in series B funding from WiL (lead investor), Sony Innovation Fund (lead investor), Globis Capital Partners (lead investor), SPARX Group, SMBC Venture Capital, Ryoyo Electro Corporation, Japan Post Capital, Innovation Growth Ventures, and Daiwa Corporate InvestmentDaiwa Corporate Investment. The company plans on using their series B funding to fund clinical trials for its early detection software. The director of Globis Capital, Satoshi Fukushima, made the following statement about AI Medical Service after participating in the company's series B funding round:

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 1 Apr, 2020
Edits made to:
Article (+13/-13 characters)
Article

On August 10, 2018 AI Medical Service announced raising ¥1 billion in series A funding from Incubate FundIncubate Fund.

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 1 Apr, 2020
Edits made to:
Article (+7/-7 characters)
Article

AI Medical Service is an artificial intelligence and healthcare company making software for the early detection of gastrointestinal cancers that is headquartered in ToshimaToshima, Tokyo and was founded in 2017 by Tomohiro Tada. The company's software analyzes endoscope images to support endoscopists and help doctors make diagnoses.

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 1 Apr, 2020
Edits made to:
Article (+23/-23 characters)
Article

On October 4, 2019 AI Medical Service announced raising ¥4.6 billion ($42.9 million USD) in series B funding from WiL (lead investor), Sony Innovation Fund (lead investor), Globis Capital PartnersGlobis Capital Partners (lead investor), SPARX Group, SMBC Venture Capital, Ryoyo Electro Corporation, Japan Post Capital, Innovation Growth Ventures, and Daiwa Corporate Investment. The company plans on using their series B funding to fund clinical trials for its early detection software. The director of Globis Capital, Satoshi Fukushima, made the following statement about AI Medical Service after participating in the company's series B funding round:

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 1 Apr, 2020
Edits made to:
Article (+20/-20 characters)
Article

On October 4, 2019 AI Medical Service announced raising ¥4.6 billion ($42.9 million USD) in series B funding from WiL (lead investor), Sony Innovation FundSony Innovation Fund (lead investor), Globis Capital Partners (lead investor), SPARX Group, SMBC Venture Capital, Ryoyo Electro Corporation, Japan Post Capital, Innovation Growth Ventures, and Daiwa Corporate Investment. The company plans on using their series B funding to fund clinical trials for its early detection software. The director of Globis Capital, Satoshi Fukushima, made the following statement about AI Medical Service after participating in the company's series B funding round:

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.